Society for Immunotherapy of Cancer

ADVANCES IN Cancer IMMUNOTHERAPY™

Immunotherapy for the Treatment of Genitourinary Malignancies

Nancy B. Davis, MD

Associate Professor of Medicine & Urology

Vanderbilt University Medical Center

AAEM AMERICAN ACADEMY OF EMERGENCY MEDICINE CHAMPION OF THE EMERGENCY PHYSICIAN

ACCC Association of Community Cancer Centers

HOPA Hematology/Oncology Pharmacy Association

Society for Immunotherapy of Cancer

Disclosures

- Research Funding (to Institution)
  - AstraZeneca, Hoffman-LaRoche, Pfizer, Merck, Incyte, Mirati Therapeutics, Seattle Genetics/Astellas, Calithera Biosciences, Taris BioMedical, Immunomedics, Bristol-Myers Squibb, Jounce Therapeutics
- I will be discussing non-FDA approved indications during my presentation.

Immunotherapy for Metastatic Kidney Cancer (Renal Cell Carcinoma; RCC)

Surgically resectable → Oligo-metastatic → Metastatic



History of Immunotherapy in mRCC



Resurgence of interest in immunotherapy

FDA-approved Immunotherapies for mRCC

Drug	Approved	Indication	Dose
High dose Interleukin-2	1992	Metastatic RCC	600,000 International Units/kg (0.037 mg/kg) IV q8hr infused over 15 minutes for a maximum 14 doses, THEN 9 days of rest, followed by a maximum of 14 more doses (1 course)
Interferon-a + bevacizumab	2009	Clear cell RCC	IFN 9 MIU s.c. three times a week + bev 10 mg/kg Q2W
Nivolumab	2015	Clear cell RCC refractory to prior VEGF targeted therapy	3mg/kg or 240mg IV Q2W or 480mg IV Q4W
Nivolumab +ipilimumab	2018	Clear cell RCC, treatment naïve	3mg/kg nivo plus 1mg/kg ipi Q3W x 4 doses then nivo maintenance at flat dosing
Pembrolizumab + axitinib	2019	Advanced RCC, Treatment naïve	200 mg pembro Q3W + 5 mg axitinib twice daily
Avelumab + axitinib	2019	Advanced RCC, Treatment naïve	800 mg avelumab Q2W + 5 mg axitinib twice daily

High Dose IL-2 in mRCC

- 20 year analysis of 259 patients
- ORR = 20%
  - 9% CR (n = 23)
  - 12% PR (n = 30)
- Median duration of response = 15.5 months
- Median OS = 19 months



Klapper et al. Cancer 2008

Second-Line Nivolumab in mRCC

- CheckMate 025 Phase III trial
- Metastatic, clear-cell disease
- One or two previous antiangiogenic treatments
- Nivolumab (3 mg/kg IV Q2W) vs everolimus (10 mg daily)



Motzer et al. NEJM 2015

Second-Line Nivolumab in mRCC

PD-L1 subgroups

PD-L1 ≥ 1%



PD-L1 < 1%



Motzer et al. NEJM 2015

First-line Nivolumab + Ipilimumab in mRCC



Nivolumab = anti-PD-1 antibody Ipilimumab = anti-CTLA-4 antibody

IMDC = International Metastatic RCC Database Consortium

Escudier et al. ESMO 2017

First-line Nivolumab + Ipilimumab in mRCC by IMDC Risk: overall survival

CheckMate 214

Follow-up
= 30 months

Intermediate/poor risk

Median OS, months (95% CI)	
NIVO+IPI	NR (35.6–NE)
SUN	26.6 (22.1–33.4)

HR (95% CI), 0.66 (0.54–0.80)
P < 0.0001



No. at risk

NIVO+IPI	425	399	372	348	332	317	306	287	270	253	233	183	90	34	2	0
SUN	422	388	353	318	290	257	236	220	207	194	179	144	75	29	3	0

Favorable risk

Median OS, months (95% CI)	
NIVO+IPI	NR (NE)
SUN	NR (NE)

HR (95% CI), 1.22 (0.73–2.04)
P = 0.4426



No. at risk

NIVO+IPI	125	124	120	116	111	108	104	102	101	98	94	88	71	24	2	0
SUN	124	119	119	117	114	110	109	105	103	101	96	88	70	26	2	0

Tannir et al. ASCO GU 2019

First-line Pembrolizumab + axitinib in advanced RCC: overall survival

KEYNOTE-426: OS in the ITT Population



Rini, ASCO 2019

First-line avelumab + axitinib in mRCC: progression-free survival

- Primary Endpoint: PFS and OS in PD-L1+
- Median PFS – 13.8 mo vs 7.2 mo (HR 0.61; 95% CI, 0.47–0.79)
- ORR: 61.9% vs 29.7
- OS data: immature

JAVELIN 101 : PFS in the PD-L1+ Population



Motzer, NEJM 2019.

In Development: First-line atezolizumab + bevacizumab in PD-L1+ mRCC

Immotion151



Rini, The Lancet 2019.

In Development: First-line atezolizumab + bevacizumab: molecular signatures



Identification of gene signatures based on association with clinicaloutcome

- T_{eff}: *CD8a*, *IFNG*, *PRF1*, *EOMES*, *CD274*
- Angio: *VEGFA*, *KDR*, *ESM1*, *PECAM1*, *CD34*, *ANGPTL4*

Rini et al, ESMO 2018

In Development: First-line atezolizumab + bevacizumab: molecular signatures

Angiogenesis





Immune





Rini et al, ESMO 2018

Front-line phase 3 trials with immunotherapy agents (efficacy summary)

	CheckMate 214	KEYNOTE-426	JAVELIN 101	IMmotion151
Intervention	Ipilimumab + Nivolumab	Pembrolizumab + Axitinib	Avelumab + Axitinib	Atezolizumab + Bevacizumab
Comparator	Sunitinib	Sunitinib	Sunitinib	Sunitinib
Primary Endpoint	OS, PFS, ORR in int/poor risk	OS, PFS	PFS, OS in PD-L1+	PFS in PD-L1+; OS
mOS, months	NR vs 37.9 (30 mo min followup)	NR vs NR (median 12.8 mo followup)	Not reported	33.6 vs 34.9 (median 24 mo followup)
PFS, months	9.7 vs 9.7	15.1 vs 11.1	13.8 vs 7.2	11.2 vs 7.7
ORR (ITT), %	41% vs 34%	59.3% vs 35.7%	51.4% vs 25.7%	37% vs 33%
CR rate (ITT)	10.5% vs 1.8%	5.8% vs 1.9%	3.4% vs 1.8%	5% vs 2%

IIT: Intent-to-Treat; PFS: progression-free survival; ORR: overall response rate; OS: overall survival

Tannir, ASCO GU 2019.
Rini, NEJM 2019.
Motzer, NEJM 2019.
Rini, Lancet 2019.

Ongoing front-line phase 3 trials with immunotherapy agents for front-line ccRCC

Trial number	Trial Name	Treatment Arm	Comparator Arm	Population Size	Primary End Point
NCT03141177	CheckMate 9ER	Cabozantinib + Nivolumab	Sunitinib	630	PFS
NCT02811861	CLEAR	Lenvatinib + Pembrolizumab or Everolimus	Sunitinib	1050	PFS
NCT03729245	CA045002	NKTR-214 + Nivolumab	Sunitinib	600	ORR, OS
NCT03937219	COSMIC-313	Cabozantinib + Ipilimumab + Nivolumab	Sunitinib	676	PFS

PFS: progression-free survival; ORR: overall response rate; OS: overall survival

In Development: First-line pembrolizumab monotherapy in mRCC KEYNOTE - 427



	N = 110
Confirmed ORR, % (95% CI)	36.4
CR, %	3 (3)
PR, %	37 (34)
DCR, %	57 (47-67)
DOR, median (range), mo	Not Reported
DOR ≥ 6 mo (responders), %	77

Donskov et al. ESMO 2018
Tykodi et al, ASCO 2019

Immunotherapy for Metastatic Bladder Cancer (Urothelial Carcinoma; UC)

Non-Muscle Invasive → Muscle Invasive → Metastatic

TNM	TIS	T_a	T_1	T_{2A}	T_{2B}	T_{3B}	T_{4A}
JSM	0	0	A	B_1	B_2	C	D_1



Approved checkpoint inhibitors for mUC – *cisplatin refractory*

Drug	Approved	Indication	Dose
Atezolizumab	2016 (2018)	Advanced/metastatic UC	1200 mg Q3W
Avelumab	2017	Advanced/metastatic UC	10 mg/kg Q2W
Durvalumab	2017	Advanced/metastatic UC	10 mg/kg Q2W
Nivolumab	2017	Advanced/metastatic UC	240 mg Q2W or 480 mg Q4W
Pembrolizumab	2017 (2018)	Advanced/metastatic UC	200 mg Q3W

Approved checkpoint inhibitors for mUC – *cisplatin ineligible*

Drug	Approved	Indication	Dose
Atezolizumab	2017 (2018)	Advanced/metastatic UC (PD-L1 ≥5%)	1200 mg Q3W
Pembrolizumab	2017 (2018)	Advanced/metastatic UC (PD-L1 CPS ≥10)	200 mg Q3W

June 2018

FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients

- Locally advanced or metastatic urothelial carcinoma and ineligible for cisplatin-based chemo and tumor PD-L1 (CPS ≥ 10, pembro; IC ≥ 5% tumor area, atezo)
- Patients ineligible for any platinum-containing chemotherapy regardless of PD-L1 status

Tumor Mutational Burden (TMB) May Signal Responses with PD-1 Blockade

Atezolizumab in mUC



Rosenberg et al. Lancet 2016

In development: Ipilimumab + Nivolumab CheckMate 032

ORR by Baseline Tumor PD-L1 Expression per Investigator



13

Rosenberg, ESMO 2018

In development: Ipilimumab + Nivolumab CheckMate 032



	NIVO3 (N = 78)	NIVO3+IPI1 (N = 104)	NIVO1+IPI3 (N = 92)
Events, n (%)	56 (72)	81 (78)	46 (50)
Median OS (95% CI), months	9.9 (7.3–21.1)	7.4 (5.6–11.0)	15.3 (10.1–27.6)

Rosenberg, ESMO 2018

The Spectrum of Prostate Cancer



Sipuleucel-T in mCRPC

PROVENGE 2010

First anti-cancer therapeutic vaccine





HR 0.78; 95% CI, 0.61-0.98, p=0.03)

Drake et al. Curr Opin Urol 2010
Kantoff et al. NEJM 2010

Sipuleucel-T in mCRPC

PROCEED 2019

- Post-hoc analysis of Phase 3 trial PROCEED (N = 1902 mCRPC patients)
- African-Americans (AA) = 438; Caucasians (CAU) = 219
- Median OS = 35.2 (AA) vs 29.9 mo (CAU); HR 0.81, 95% CI 0.68–0.97; p = 0.03.
- AA race was independently associated with prolonged OS on multivariate analysis (HR 0.60, 95% CI 0.48–0.74; p < 0.001)



Sartor et al. ASCO 2019

Limited efficacy of Checkpoint Inhibitors in mCRPC

No FDA-approved CIs for mCRPC

KEYNOTE-199 (Pembrolizumab)



- Pembrolizumab is approved for all Microsatellite Instability-High (MSI-H) solid tumors
- MSI-H incidence is low in PC
  - Localized PC ~2%
  - Autopsy series of mCRPC ~12%
- MSI testing may offer pembrolizumab as an option

DeBono et al. ASCO 2018

In development: nivolumab + ipilimumab in mCRPC

- Checkmate 650
- Nivo 1 mg/kg + Ipi 3 mg/kg Q3W for 4 doses, then Nivo 480 mg Q4W
- Progressed after 2nd-gen hormonal: 26% response @ 11.9 mo, 2 CR
- Progressed after chemo+hormonal: 10% response @ 13.5 mo, 2 CR
- Higher ORR in:
  - PD-L1 > 1%
  - DNA damage repair deficient
  - homologous recombination deficiency
  - high tumor mutational burden

Sharma, GU Cancer Symp 2019.

Future Combinations in mCRPC to Engage Immune System

- Hormonal therapy
- Radiation
- Radium-223
- PARP inhibitors
- Chemotherapy
- New targets



Stein et al. Asian J Andrology 2014

irAEs with Immune Checkpoint Inhibitors in GU Cancers - Meta-analysis of 8 studies

Similar incidence overall

Adverse event	Incidence, any grade (GU only trials) (%)	Incidence, grades 3–5 (GU only trials) (%)	Incidence any grade (non-GU clinical trials) (%)	Incidence, grades 3–5 (non-GU clinical trials) (%)
Hypothyroid/ thyroiditis	0.8–9	0–0.6	3.9–12	0–0.1
Diabetes/DKA	0–1.5	0–0.7	0.8–0.8	0.4–0.7
LFT changes/ hepatitis	1.5–5.4	1–3.8	0.3–3.4	0.3–2.7
Pneumonitis	2–4.4	0–2	1.8–3.5	0.25–1.9
Encephalitis	NR	NR	0.2–0.8	0.0–0.2
Colitis/diarrhea	1–10	1–10	2.4–4.1	1.0–2.5
Hypophysitis	0–0.5	0–0.2	0.2–0.9	0.2–0.4
Renal Dysfunction/ nephritis	0.3–1.6	0–1.6	0.3–4.9	0.0–0.5
Myositis	0.8–5	0–0.8	NR	NR

Maughan et al. Front Oncol 2017

Conclusions

- The role of immunotherapy in GU malignancies is increasing
- In RCC, many front-line checkpoint inhibitor options are approved
- Multiple checkpoint inhibitors approved for advanced/metastatic urothelial carcinoma
- Low immune engagement in prostate cancer has limited the application of immunotherapy in this disease

Additional Resources



Rini *et al. Journal for ImmunoTherapy of Cancer* (2016) 4:81
DOI 10.1186/s40425-016-0180-7

Journal for ImmunoTherapy of Cancer

POSITION ARTICLE AND GUIDELINES — Open Access

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Brian I. Rini[1], David F. McDermott[2], Hans Hammers[3], William Bro[4], Ronald M. Bukowski[5], Bernard Faba[6], Jo Faba[6], Robert A. Figlin[7], Thomas Hutson[8], Eric Jonasch[9], Richard W. Joseph[10], Bradley C. Leibovich[11], Thomas Olencki[12], Allan J. Pantuck[13], David I. Quinn[14], Virginia Seery[2], Martin H. Voss[15], Christopher G. Wood[9], Laura S. Wood[1] and Michael B. Atkins[16*]



McNeel *et al. Journal for ImmunoTherapy of Cancer* (2016) 4:92
DOI 10.1186/s40425-016-0198-x

Journal for ImmunoTherapy of Cancer

POSITION ARTICLE AND GUIDELINES — Open Access

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Douglas G. McNeel[1], Neil H. Bander[2], Tomasz M. Beer[3], Charles G. Drake[4], Lawrence Fong[5], Stacey Harrelson[6], Philip W. Kantoff[7], Ravi A. Madan[8], William K. Oh[9], David J. Peace[10], Daniel P. Petrylak[11], Hank Porterfield[12], Oliver Sartor[13], Neal D. Shore[6], Susan F. Slovin[7], Mark N. Stein[14], Johannes Vieweg[15] and James L. Gulley[16*]



Kamat *et al. Journal for ImmunoTherapy of Cancer* (2017) 5:68
DOI 10.1186/s40425-017-0271-0

Journal for ImmunoTherapy of Cancer

POSITION ARTICLE AND GUIDELINES — Open Access

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Ashish M. Kamat[1*], Joaquim Bellmunt[2], Matthew D. Galsky[3], Badrinath R. Konety[4], Donald L. Lamm[5], David Langham[6], Cheryl T. Lee[7], Matthew I. Milowsky[8], Michael A. O'Donnell[9], Peter H. O'Donnell[10], Daniel P. Petrylak[11], Padmanee Sharma[12], Eila C. Skinner[13], Guru Sonpavde[14], John A. Taylor III[15], Prasanth Abraham[16] and Jonathan E. Rosenberg[17]

Case Studies

Case Study 1

38 y/o man presents with 1-2 week history of nonproductive cough with occasional hemoptysis. 2 years ago, he underwent cytoreductive nephrectomy for a pT3pNx clear cell renal cell carcinoma. Due to relocating with a new job, he has not had follow up for the past 1 year. He is still working full time.

Work up includes CXR which reveals pulmonary nodules vs infiltrates and CT chest / abdomen / pelvis shows bilateral pulmonary nodules along with a 5cm soft tissue mass in the right nephrectomy bed and a hepatic lesion suspicious for metastatic disease. Labs include normal creatinine and LFTs, WBC 4.8, ANC 2800, Hgb 13.5 g/dl, PLT 250k, Albumin 3.8 mg/dl and Ca++ 10.0 mg/dl.

What systemic therapy would you consider for this patient?

A. Sunitinib 50 mg/day 4 weeks on, 2 weeks off

B. Ipilimumab + nivolumab

C. High dose IL-2

D. IO therapy + axitinib

Case Study 1

- Need to know risk stratification
- Two systems: MSKCC and IDMC
- Vastly different anticipated OS dependent upon risk group

Table 1: Prognostication utilization MSKCC6 or IMDC5 Risk Factors

RISK FACTOR	MSKCC RISK FACTORS	IMDC RISK FACTORS
Time from diagnosis to systemic treatment < 1 year	X	X
Hemoglobin less than lower limit of normal	X	X
Calcium greater than upper limit of normal	X	X
Performance Status (Karnofsky) <80%	X	X
LDH greater than 1.5 upper limit of normal	X	
Neutrophil count greater than upper limit of normal		X
Platelet count greater than upper limit of normal		X

0 Risk Factors = Favorable Prognosis, 1-2 Risk Factors = Intermediate, >2 Risk Factors = Poor

Motzer RJ, et al. *J Clin Oncol*. 2002; 20:289-296. Mekhail TM, et al. *J Clin Oncol*. 2005;23:832-841.

Case Study 1

38 y/o man presents with 1-2 week history of nonproductive cough with occasional hemoptysis. 2 years ago, he underwent cytoreductive nephrectomy for a pT3pNx clear cell renal cell carcinoma. Due to relocating with a new job, he has not had follow up for the past 1 year. He is still working full time.

Work up includes CXR which reveals pulmonary nodules vs infiltrates and CT chest / abdomen / pelvis shows bilateral pulmonary nodules along with a 5cm soft tissue mass in the right nephrectomy bed and a hepatic lesion suspicious for metastatic disease. Labs include normal creatinine and LFTs, WBC 4.8, ANC 2800, Hgb 13.5 g/dl, PLT 250k, Albumin 3.8 mg/dl and Ca++ 10.0 mg/dl.

What systemic therapy would you consider for this patient?

A. Sunitinib 50 mg/day 4 weeks on, 2 weeks off

B. Ipilimumab + nivolumab

C. High dose IL-2

D. IO therapy + axitinib

Case Study 1

Patient tolerates therapy well overall, gains back 10# and has no further respiratory symptoms. At his 1st scan after 3 months of therapy, his pulmonary metastaswes and soft tissue mass are stable, but the liver metastasis is 4 mm larger. There is no new disesae.

What should you recommend now?

A. Stop therapy for progression and consider 2nd line therapy or a clinical trial
B. Recommend hospice
C. Consider this pseudo-progression and continue with current therapy
D. Try to dose escalate the axitinib

Case Study 1

Patient tolerates therapy well overall, gains back 10# and has no further respiratory symptoms. At his 1st scan after 3 months of therapy, his pulmonary metastases and soft tissue mass are stable, but the liver metastasis is 4 mm larger. There is no new disease.

What should you recommend now?

A. Stop therapy for progression and consider 2nd line therapy or a clinical trial
B. Recommend hospice
C. Consider this pseudo-progression and continue with current therapy
D. Try to dose escalate the axitinib

Case Study 2

72 y/o woman presents with gross hematuria and urinary retention. CT urogram shows a filling defect in the right bladder as well as bilateral external iliac lymphadenopathy measuring up to 2.6 cm. A TURBT is done which reveals high grade urothelial cancer invasive into the lamina propria and muscularis propria. Complete staging with CT chest multiple lung metastases in the left lung.

She is sent by Urology to discuss systemic therapy. What is the next step?

A. Next generation sequencing
B. Start durvalumab therapy
C. Start gemcitabine, carboplatin and bevacizumab
D. Enroll in hospice

Case Study 2

72 y/o woman presents with gross hematuria and urinary retention. This is interfering with her golf game. CT urogram shows a filling defect in the right bladder as well as bilateral external iliac lymphadenopathy measuring up to 2.6 cm. A TURBT is done which reveals high grade urothelial cancer invasive into the lamina propria and muscularis propria. Complete staging with CT chest reveals multiple lung metastases in the left lung.

She is sent by Urology to discuss systemic therapy. What is the next step?

A. Next generation sequencing
B. Start durvalumab therapy
C. Start gemcitabine, carboplatin and bevacizumab
D. Enroll in hospice

Case Study 2

Work up shows CrCl 35 ml/min/m2. NGS is sent on the patient's tumor and reveals PD-L1 expression 25%, CPS. Patient is reluctant to undergo chemotherapy in general. What is her best 1st line treatment option?

A. gemcitabine + cisplatin
B. gemcitabine + carboplatin
C. single agent paclitaxel
D. atezolizumab or pembrolizumab

Case Study 2

Work up shows CrCl 35 ml/min/m2. NGS is sent on the patient's tumor and reveals PD-L1 expression 25%. Patient is reluctant to undergo chemotherapy in general. What is her best 1st line treatment option?

A. gemcitabine + cisplatin
B. gemcitabine + carboplatin
C. single agent paclitaxel
D. atezolizumab or pembrolizumab